DDInter1945 DDInter1435
Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Vorapaxar {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Vorapaxar {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hemin
Vorapaxar {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Vorapaxar {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Vorapaxar {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Vorapaxar may cause a minor interaction that can limit clinical effects when taken with Chamomile
Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Vorapaxar may lead to a major life threatening interaction when taken with Anagrelide
Vorapaxar may lead to a major life threatening interaction when taken with Troleandomycin